Otto Metzger-Filho

Summary

Affiliation: Institut Jules Bordet
Country: Belgium

Publications

  1. doi Larotaxel: broadening the road with new taxanes
    Otto Metzger-Filho
    Research Fellow, Jules Bordet Institute, 121, Bd de Waterloo, 1000 Brussels, Belgium
    Expert Opin Investig Drugs 18:1183-9. 2009
  2. doi Prevention and management of major side effects of targeted agents in breast cancer
    Otto Metzger Filho
    Institut Jules Bordet, 121 Boulevard de Waterloo, Brussels, Belgium
    Crit Rev Oncol Hematol 84:e79-85. 2012
  3. doi Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis
    Otto Metzger Filho
    Institut Jules Bordet, 121 Boulevard de Waterloo, B 1000 Brussels, Belgium
    Crit Rev Oncol Hematol 77:20-9. 2011
  4. doi Dissecting the heterogeneity of triple-negative breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1879-87. 2012
  5. doi Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
    Kamal S Saini
    Breast International Group, Brussels, Belgium Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Cancer Treat Rev 39:935-46. 2013
  6. doi Beyond trastuzumab: new treatment options for HER2-positive breast cancer
    Kamal S Saini
    Breast International Group, Brussels, Belgium
    Breast 20:S20-7. 2011
  7. ncbi Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives
    Otto Metzger-Filho
    Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium
    Curr Clin Pharmacol 5:166-77. 2010
  8. pmc Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 8:e66848. 2013
  9. pmc Targeted therapies in breast cancer: are heart and vessels also being targeted?
    Carmen Criscitiello
    Department of Medical Oncology, Jules Bordet Institute, Universite Libre de Bruxelles, 1000 Brussels, Belgium
    Breast Cancer Res 14:209. 2012
  10. doi Neoadjuvant chemotherapy and targeted therapies: a promising strategy
    Otto Metzger-Filho
    Medical Oncology Clinic, Jules Bordet Institute, Brussels 1000, Belgium
    J Natl Cancer Inst Monogr 2011:116-9. 2011

Detail Information

Publications17

  1. doi Larotaxel: broadening the road with new taxanes
    Otto Metzger-Filho
    Research Fellow, Jules Bordet Institute, 121, Bd de Waterloo, 1000 Brussels, Belgium
    Expert Opin Investig Drugs 18:1183-9. 2009
    ..The development path of this drug, its core clinical data and future treatment perspectives are discussed in this article...
  2. doi Prevention and management of major side effects of targeted agents in breast cancer
    Otto Metzger Filho
    Institut Jules Bordet, 121 Boulevard de Waterloo, Brussels, Belgium
    Crit Rev Oncol Hematol 84:e79-85. 2012
    ..We critically analyse the available evidence and provide some insights on how to manage these toxicities in the clinical setting...
  3. doi Genomic Grade Index: An important tool for assessing breast cancer tumor grade and prognosis
    Otto Metzger Filho
    Institut Jules Bordet, 121 Boulevard de Waterloo, B 1000 Brussels, Belgium
    Crit Rev Oncol Hematol 77:20-9. 2011
    ....
  4. doi Dissecting the heterogeneity of triple-negative breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    J Clin Oncol 30:1879-87. 2012
    ....
  5. doi Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
    Kamal S Saini
    Breast International Group, Brussels, Belgium Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    Cancer Treat Rev 39:935-46. 2013
    ..In this article, we present a review of the current relevant pre-clinical and clinical data and discuss the rationale for dual inhibition of these pathways in the treatment of BC patients...
  6. doi Beyond trastuzumab: new treatment options for HER2-positive breast cancer
    Kamal S Saini
    Breast International Group, Brussels, Belgium
    Breast 20:S20-7. 2011
    ..Therefore, to avoid unnecessary toxicities and costs, it is critical to intensify the research for biomarkers that can identify those patients most likely to benefit from specific targeted therapies...
  7. ncbi Molecular targeted therapy in prevalent tumors: learning from the past and future perspectives
    Otto Metzger-Filho
    Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium
    Curr Clin Pharmacol 5:166-77. 2010
    ..Initial attempts to block mTOR in breast cancer, the magnitude of benefit obtained with anti-EGFR therapy in lung cancer, and the narrowing use of anti-EGFR therapy in colon cancer based on KRAS status are discussed...
  8. pmc Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer
    Otto Metzger-Filho
    Institut Jules Bordet, Universite Libre de Bruxelles, Brussels, Belgium
    PLoS ONE 8:e66848. 2013
    ..In this prospective study we sought to evaluate the feasibility of performing GGI in routine clinical practice and its impact on treatment recommendations...
  9. pmc Targeted therapies in breast cancer: are heart and vessels also being targeted?
    Carmen Criscitiello
    Department of Medical Oncology, Jules Bordet Institute, Universite Libre de Bruxelles, 1000 Brussels, Belgium
    Breast Cancer Res 14:209. 2012
    ..In this review, we aim to assess the incidence of cardiac adverse events associated with targeted therapies designed to block HER2 and angiogenic pathways...
  10. doi Neoadjuvant chemotherapy and targeted therapies: a promising strategy
    Otto Metzger-Filho
    Medical Oncology Clinic, Jules Bordet Institute, Brussels 1000, Belgium
    J Natl Cancer Inst Monogr 2011:116-9. 2011
    ..This implies that the time between drug discovery and regulatory approval can be significantly shortened, which ultimately benefits patients...
  11. doi Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01)
    Hatem A Azim
    Department of Medical Oncology, Institut Jules Bordet and l Université Libre de Bruxelles, Boulevard de Waterloo 121, 1000 Brussels, Belgium
    Breast Cancer Res Treat 133:387-91. 2012
    ..We are currently initiating a collaboration to collect similar data from the other large adjuvant trastuzumab trials to confirm these findings...
  12. doi Changing the clinical picture of challenging tumors: tales becoming reality?
    Camilo Moulin
    Jules Bordet Institute, 121 Bd de Waterloo, 1000 Brussels, Belgium
    Future Oncol 5:785-802. 2009
    ..This article aims to evaluate new insights and potential gains obtained with new therapies in a particular group of tumors: those rarely debated in clinical practice, but which still pose a considerable challenge to clinical oncology...
  13. doi Management of metastatic HER2-positive breast cancer progression after adjuvant trastuzumab therapy - current evidence and future trends
    Otto Metzger-Filho
    Institut Jules Bordet, Brussels, Belgium
    Expert Opin Investig Drugs 19:S31-9. 2010
    ..Better understanding of HER2 functions and interactions of different signalling pathways will be essential for optimal targetted therapies...
  14. doi Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial
    Otto Metzger-Filho
    Dana Farber Cancer Institute, Harvard School of Public Health, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 31:1954-60. 2013
    ..To evaluate the benefit of adjuvant trastuzumab in patients diagnosed with human epidermal growth factor receptor 2 (HER2) -positive invasive lobular carcinoma (ILC) enrolled onto the Herceptin Adjuvant (HERA) trial...
  15. pmc Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence
    José R Rossari
    Institut Jules Bordet, Universite Libre de Bruxelles, boulevard de Waterloo, 125, 1000 Brussels, Belgium
    J Oncol 2012:417673. 2012
    ..Conclusions. Bevacizumab combined with chemotherapy in the first-line treatment of MBC significantly improved ORR and PFS, but also increased grade 3-4 toxicities. No significant OS advantage was observed...
  16. pmc Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad?
    Andrea Gombos
    Medical Oncology Clinic, Institut Jules Bordet, 121 Boulevard de Waterloo, 1000, Brussels, Belgium
    Invest New Drugs 30:2433-42. 2012
    ..We also tried to extract based on clinical and translational data some candidate biomarkers that could help better to select patient population who potentially could benefit most from this therapeutic approach...
  17. doi First-line systemic treatment of ovarian cancer: a critical review of available evidence and expectations for future directions
    Otto Metzger-Filho
    Institut Jules Bordet, 121 Boulevard de Waterloo, Brussels, Belgium
    Curr Opin Oncol 22:513-20. 2010
    ..In this article, we critically review the available clinical evidence for the choice of first-line chemotherapy in EOC and discuss promising therapeutic strategies...